Literature DB >> 3801071

Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.

J S Bomalaski, G Lluberas, H R Schumacher.   

Abstract

We aspirated synovial fluid from the knees of 50 patients with asymptomatic, nontophaceous gout, in whom synovial fluid monosodium urate (MSU) crystals had previously been documented in the knees or other joints. Fifty-eight percent of these asymptomatic patients had MSU crystals in their knee joints. Serum uric acid levels, serum creatinine levels, volume of synovial fluid aspirated, and cell counts of the aspirated fluid did not differentiate the MSU crystal-positive group from the group without MSU crystals. Clinical factors such as alcohol abuse, coronary heart disease, hypertension, duration of gout, duration of the intercritical period, and drug therapy did not differentiate the 2 groups. Nineteen patients consented to aspiration of their other knee. Seven of these patients (37%) had MSU crystals bilaterally, and 6 patients (32%) had them unilaterally. The implications of the persistence of MSU crystals (including those in intracellular locations) in many patients, despite normalization of serum uric acid levels, should be determined. Knee joint aspiration is a sensitive method for the demonstration of MSU crystals in asymptomatic patients. The procedure might also be useful in documenting these crystals in patients who have had attacks of arthritis with features consistent with a diagnosis of gout, but in whom MSU crystals have not been documented.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801071     DOI: 10.1002/art.1780291209

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  [Gouty arthritis].

Authors:  A-K Tausche; M Aringer
Journal:  Z Rheumatol       Date:  2016-11       Impact factor: 1.372

2.  Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study.

Authors:  Giovambattista Desideri; Agostino Virdis; Edoardo Casiglia; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-02-09

Review 3.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

Authors:  U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

4.  An MRI assessment of chronic synovial-based inflammation in gout and its correlation with serum urate levels.

Authors:  John D Carter; Michelle Patelli; Scott R Anderson; Neelesh Prakash; Ernesto J Rodriquez; Helen Bateman; Ashley Sterrett; Joanne Valeriano; Louis R Ricca
Journal:  Clin Rheumatol       Date:  2014-05-07       Impact factor: 2.980

5.  Tophus-derived monosodium urate monohydrate crystals are biologically much more active than synthetic counterpart.

Authors:  A Stankovíc; P Front; A Barbara; D R Mitrovíc
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

6.  Role of ultrasound and other advanced imaging in the diagnosis and management of gout.

Authors:  Ralf G Thiele
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

Review 7.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Goals of gout treatment: a patient perspective.

Authors:  Jasvinder A Singh
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

9.  Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.

Authors:  Edward Roddy; Weiya Zhang; Michael Doherty
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

10.  Serum/Synovial Fluid Urate Ratio as an Indicator for Distinguishing Gouty Arthritis From Other Arthritides.

Authors:  Shunfei Lu; Qiankun Zhang; Yan Zhou
Journal:  Arch Rheumatol       Date:  2018-05-20       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.